8-K: Galectin Therapeutics Announces Updated Corporate Presentation and Clinical Trial Results for Belapectin

Galectin Therapeutics released an updated corporate presentation highlighting clinical trial results for Belapectin in MASH cirrhosis and cancer immunotherapy, with a focus on the NAVIGATE trial and its findings on varices prevention.

Summary

• Galectin Therapeutics has updated its corporate presentation, focusing on the development of galectin-based therapeutics for chronic liver diseases and cancer.
• The presentation highlights Belapectin, a galectin-3 inhibitor, and its potential in treating MASH cirrhosis and portal hypertension.
• The NAVIGATE trial, a Phase 2b/3 study, evaluated Belapectin for the prevention of varices in patients with MASH cirrhosis and portal hypertension.
• The 18-month primary analysis of the NAVIGATE trial showed a 49% reduction in the incidence of new varices in the per-protocol population with the 2 mg/kg LBM dose.
• The company is exploring partnership opportunities and expects biomarker data and longer-term outcomes data (36-month data) from available patients by the end of the first quarter of 2025.
• Belapectin, in combination with pembrolizumab, has shown encouraging clinical responses in difficult-to-treat cancers in a Phase 1 trial.
• An IND has been filed and approval to proceed has been received from the FDA for a Head & Neck cancer study.

Sentiment

Score: 6

Explanation: The document presents mixed results. While there are encouraging findings regarding the reduction of varices in the per-protocol population and the safety profile of Belapectin, the lack of statistical significance in the primary endpoint and the higher dropout rate temper the overall sentiment. The potential for cancer immunotherapy is a positive, but it's still in early stages.

Positives

• Belapectin demonstrated a meaningful reduction in the development of new esophageal varices in patients with MASH cirrhosis and portal hypertension.
• Non-invasive markers provide supportive evidence showing a lower incidence of disease progression.
• Belapectin exhibits a clean and favorable safety profile with a low rate of discontinuation due to adverse events and no drug-related serious adverse events.
• The distinct MOA of belapectin as Galectin 3 inhibitor positions it as a favorable and complementary candidate for combination therapy in MASH cirrhosis.
• Belapectin, in combination with pembrolizumab, has shown encouraging clinical responses in difficult-to-treat cancers in a Phase 1 trial.

Negatives

• The NAVIGATE trial's primary endpoint in the ITT population did not achieve statistical significance.
• The study experienced a higher dropout rate than expected (18.3% observed vs. 10% expected), mostly during COVID and the first 4 months.
• The initial sample size estimation assumed a 52.5% lower varices incidence with Belapectin vs. placebo, which was not observed.
• There was a lack of dose response at higher doses of Belapectin in the NAVIGATE trial.

Risks

• The company may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow it to complete its clinical trials or further develop and/or fund any future studies or trials.
• The company has incurred operating losses since its inception, and its future success may be impacted by its ability to manage costs and finance its continuing operations.
• Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly.
• Plans regarding development, approval and marketing of any of the company's drugs are subject to change at any time based on the changing needs of the company as determined by management and regulatory agencies.

Future Outlook

The company anticipates biomarker data and longer-term outcomes data (36-month data) from available patients by the end of the first quarter of 2025 and is exploring partnership opportunities.

Industry Context

MASH cirrhosis represents a significant market opportunity with no FDA-approved treatments, and Belapectin is positioned as a novel therapy with firstand best-in-class potential in this area. The company is also exploring the use of Belapectin in combination with checkpoint inhibitors for cancer immunotherapy, which is a growing area of research and development in the pharmaceutical industry.

Comparison to Industry Standards

• The document mentions that there are no approved therapies to reverse portal hypertension once it develops in MASH Cirrhosis, highlighting the unmet need in this area.
• The document references the NAVIGATE trial, which is comparable to other Phase 2b/3 trials in the MASH field, such as those conducted by Intercept Pharmaceuticals (now Alizyme) with obeticholic acid (OCA) and Genfit with elafibranor, although those trials targeted fibrosis improvement rather than varices prevention.
• The document mentions Keytruda, a checkpoint inhibitor developed by Merck, as a combination therapy partner for Belapectin in cancer immunotherapy, indicating a strategy similar to other companies exploring combination therapies to enhance the efficacy of checkpoint inhibitors.

Stakeholder Impact

• Positive impact on patients with MASH cirrhosis and portal hypertension if Belapectin proves effective in preventing varices and improving liver health.
• Potential benefits for cancer patients through the combination therapy of Belapectin and checkpoint inhibitors.
• Shareholders may experience increased value if the company successfully develops and commercializes Belapectin.
• Employees may benefit from the company's growth and success.

Next Steps

• The company will continue analyses for 18-month data.
• The company will analyze 36-month data from available patients.
• The company expects biomarker data by the end of the first quarter of 2025.
• The company is exploring partnership opportunities.

Key Dates